MedTrace Logo

Use of Mesenchymal Stem Cells in Pre-term Patients With Bronchopulmonary Dysplasia.

NCT06270199 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2025-03-17

No results posted yet for this study

Summary

Bronchopulmonary dysplasia (BPD) is a disease that affects preterm newborn patients, preventing their lungs from developing properly. Allogeneic fetal stem mesenchymal cells from umbilical cord could reduce the prevalence of BPD in this patients.

Conditions

  • Bronchopulmonary Dysplasia

Interventions

BIOLOGICAL

Control

Standard treatment

BIOLOGICAL

Allogenic fetal mesenchymal stem cells from umbilical cord - three infusions

3 doses of 5 million MSC will be administered

BIOLOGICAL

Allogenic fetal mesenchymal stem cells from umbilical cord - six infusions

6 doses of 5 million MSC will be administered

Sponsors & Collaborators

  • Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

    lead OTHER

Principal Investigators

  • María Jesús del Cerro, PhD · IRYCIS. Hospital Universitario Ramón y Cajal. Madrid, Spain.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Month
Max Age
28 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-11
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06270199 on ClinicalTrials.gov